Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: GlobalData
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

US FDA Approves US Supply Of Epilepsy Drug Zonegran (zonisamide) From Eisai Co Ltd's EMEA Knowledge Centre

Monday, 14 Oct 2013 07:02pm EDT 

Eisai Co Ltd announced that the US Food and Drug Administration (FDA) has approved the US supply of the epilepsy drug Zonegran (zonisamide) from its EMEA (Europe, Middle East, Africa, Russia and Oceania) Knowledge Centre based in Hatfield, UK. The Hatfield site will manufacture and package three different strengths of Zonegran tablet for export to the US. The FDA supply approval for zonisamide follows the approval for the US supply of another Eisai epilepsy drug, Fycompa (perampanel), on 11 September 2013. The manufacturing facility at Hatfield, which also includes Eisai's EMEA sales and marketing and R&D operations, is increasing in significance to the Company's worldwide business as it continues becomes a global supply centre for products such as zonisamide and perampanel. 

Company Quote

-0.34 -0.51%
6 May 2015